Substance use disorders and COVID-19: reflections on international research and practice changes during the "poly-crisis".
addictions
alcohol
drugs
harm reduction
opioids
pandemic
treatment service
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
04
2023
accepted:
03
07
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Since March 2020, the COVID-19 pandemic has had a disproportionately high toll on vulnerable populations, coinciding with increased prevalence of alcohol-and drug-related deaths and pre-existing societal issues such as rising income inequality and homelessness. This poly-crisis has posed unique challenges to service delivery for people with substance use disorders, and innovative approaches have emerged. In this Perspectives paper we reflect on the poly-crisis and the changes to research and practice for those experiencing substance use disorders, following work undertaken as part of the InterGLAM project (part of the 2022. Lisbon Addictions conference). The authors, who were part of an InterGLAM working group, identified a range of creative and novel responses by gathering information from conference attendees about COVID-19-related changes to substance use disorder treatment in their countries. In this paper we describe these responses across a range of countries, focusing on changes to telehealth, provision of medications for opioid use disorder and alcohol harm reduction, as well as changes to how research was conducted. Implications include better equity in access to technology and secure data systems; increased prescribed safer supply in countries where this currently does not exist; flexible provision of medication for opioid use disorder; scale up of alcohol harm reduction for people with alcohol use disorders; greater involvement of people with lived/living experience in research; and additional support for research in low- and middle-income countries. The COVID-19 pandemic has changed the addictions field and there are lessons for ongoing and emerging crises.
Identifiants
pubmed: 37529435
doi: 10.3389/fpubh.2023.1201967
pmc: PMC10390069
doi:
Substances chimiques
Ethanol
3K9958V90M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1201967Informations de copyright
Copyright © 2023 Carver, Ciolompea, Conway, Kilian, McDonald, Meksi and Wojnar.
Déclaration de conflit d'intérêts
HC, AC, TC, and AM all received scholarships from InterGLAM to attend the Lisbon Addictions Conference in November 2022. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Subst Abus. 2021;42(2):140-147
pubmed: 33848451
Int J Environ Res Public Health. 2022 Nov 17;19(22):
pubmed: 36429926
Addiction. 2022 Aug;117(8):2135-2140
pubmed: 35038780
Front Public Health. 2022 Mar 15;10:846641
pubmed: 35372199
Int J Drug Policy. 2022 Dec;110:103877
pubmed: 36265326
Psychol Addict Behav. 2022 Feb;36(1):1-19
pubmed: 34807630
J Subst Abuse Treat. 2021 May;124:108283
pubmed: 33771282
Int J Drug Policy. 2022 Feb;100:103505
pubmed: 34753045
Drug Alcohol Depend. 2022 Mar 1;232:109263
pubmed: 35120807
Lancet. 2021 Jan 9;397(10269):129-170
pubmed: 33278353
Int J Drug Policy. 2019 May;67:58-62
pubmed: 30959410
Harm Reduct J. 2021 Aug 14;18(1):88
pubmed: 34391436
JAMA Psychiatry. 2021 Jul 1;78(7):767-777
pubmed: 33787832
Harm Reduct J. 2021 Dec 6;18(1):125
pubmed: 34872581
Drug Alcohol Rev. 2021 Jan;40(1):10-12
pubmed: 33029818
Lancet. 1999 Jul 3;354(9172):65-8
pubmed: 10406380
J Subst Abuse Treat. 2021 May;124:108221
pubmed: 33303254
Front Psychiatry. 2021 Apr 29;12:639393
pubmed: 34025471
Harm Reduct J. 2020 Jul 17;17(1):49
pubmed: 32680520
BMJ. 2010 Sep 16;341:c4851
pubmed: 20847018
Alcohol Clin Exp Res. 2022 Apr;46(4):498-513
pubmed: 35412673
Cochrane Database Syst Rev. 2017 Apr 27;4:CD011983
pubmed: 28447766
Lancet Gastroenterol Hepatol. 2020 Oct;5(10):886-887
pubmed: 32763197
Int J Health Policy Manag. 2020 Nov 01;9(11):486-487
pubmed: 32610805
Front Psychiatry. 2021 Feb 18;12:623649
pubmed: 33679480
Drug Alcohol Rev. 2022 May;41(4):918-931
pubmed: 35187739
Int J Law Psychiatry. 2020 Jul - Aug;71:101579
pubmed: 32768113
SSM Qual Res Health. 2021 Dec;1:100013
pubmed: 34870265
Lancet Reg Health Eur. 2022 Mar 08;15:100358
pubmed: 35531496
Drug Alcohol Depend. 2021 Nov 1;228:109065
pubmed: 34600257
Drug Alcohol Rev. 2022 May;41(4):912-917
pubmed: 34908203
Harm Reduct J. 2020 May 6;17(1):26
pubmed: 32375887
BMJ Open. 2021 Jun 9;11(6):e048353
pubmed: 34108170
Alcohol Clin Exp Res. 2020 Sep;44(9):1906-1909
pubmed: 32735694
Front Psychol. 2021 Jul 07;12:635686
pubmed: 34305710
Drug Alcohol Depend. 2021 Feb 1;219:108461
pubmed: 33454159
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Addiction. 2016 Mar;111(3):389-90
pubmed: 26860243
Int J Drug Policy. 2021 Jul;93:103237
pubmed: 33893026
J Subst Abuse Treat. 2020 Dec;119:108139
pubmed: 33138924
J Cardiovasc Dev Dis. 2022 Jan 10;9(1):
pubmed: 35050229
Int J Drug Policy. 2022 Sep;107:103787
pubmed: 35849935
Afr J Prim Health Care Fam Med. 2020 Jul 15;12(1):e1-e4
pubmed: 32787395
Harm Reduct J. 2021 Mar 3;18(1):26
pubmed: 33658042
Harm Reduct J. 2021 Jan 25;18(1):13
pubmed: 33494726
Hepatology. 2020 Sep;72(3):1102-1108
pubmed: 32369624